Bayer's (BAYRY) Q3 EBITDA comes in at €1.984B (+7.6% Y/Y), well ahead of the €1.87B analysts expected. Net income rises 42% Y/Y to €733M.
Revenue for the period was €9.64B (flat Y/Y), missing estimates by around €200M.
Growth in the pharmaceuticals business grows 3.1%, driven by Xarelto, Eylea, Stivarga, and Xofigo.
Full year outlook: Sales of €40B (versus previous guidance of €40-41B), EBITDA growth in the "mid-single-digit" range, and core earnings growth in the "high single-digits." (PR)